Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2000
10/12/2000CA2367052A1 Use of cyp2d6 inhibitors in combination therapies
10/12/2000CA2366903A1 Methods for modulating the human sexual response
10/12/2000CA2366895A1 Immunomodulating polymers
10/12/2000CA2366850A1 Method for the treatment of neurological or neuropsychiatric disorders
10/12/2000CA2366791A1 Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
10/12/2000CA2366774A1 Method of detecting endometriosis
10/12/2000CA2365961A1 Human neurogenin 3-encoding nucleotide sequences
10/12/2000CA2365825A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/12/2000CA2365500A1 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000CA2365421A1 Vesicle associated proteins
10/12/2000CA2365040A1 Hob-bp2h compositions, methods and uses thereof
10/12/2000CA2363942A1 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
10/12/2000CA2361885A1 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
10/11/2000EP1042498A1 A method of finding agonist and antagonist to human 11cb splice variant
10/11/2000EP1042482A1 Acetyl-coa-carboxylase from candida albicans
10/11/2000EP1042476A1 Insulin-like growth factor binding protein fragments and the utilization thereof
10/11/2000EP1042468A2 Low-voltage activated calcium channel compositions and methods
10/11/2000EP1042460A1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
10/11/2000EP1042456A1 Human nucleotide pyrophosphohydrolase-2
10/11/2000EP1042362A2 Human regulatory proteins
10/11/2000EP1042350A1 Inducible phosphofructokinase and the warburg effect
10/11/2000EP1042275A1 Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
10/11/2000EP1042003A1 Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
10/11/2000EP1041995A1 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
10/11/2000EP1041987A1 Opioid agonist/antagonist combinations
10/11/2000EP1041985A1 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
10/11/2000EP1041977A1 USE OF PPAR-$g(g) ACTIVATORS IN DERMATOLOGY
10/11/2000EP1041896A2 Fat blend
10/11/2000EP1041882A1 Transvascular delivery of a composition to an extravascular tissue of a mammal
10/11/2000EP0937101B1 Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them
10/11/2000EP0914116B1 Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
10/11/2000EP0778768A4 Formulations and methods for providing prolonged local anesthesia
10/11/2000CN1269832A Kay-novel immune system protein
10/11/2000CN1269727A Pharmaceutical compositions containing lyosostaphin alone or in combination with antibiotic for treatment of staphylococcal infections
10/11/2000CN1269725A Product comprising at least double stranded RNA combined with at least an antiviral agent
10/11/2000CN1269722A Method and composition for modulating responsiveness to corticosteroids
10/11/2000CN1269721A Method for increasing bone volumn using non-naturally-occuring EP selective agonists
10/11/2000CN1269720A Method of increasing bone volume
10/11/2000CN1057207C Composition for treating osteoporosis
10/10/2000US6130325 Human P24 vesicle proteins
10/10/2000US6130233 Methods and compositions for treating allergic disorders and other disorders using metabolic derivatives of astemizole
10/10/2000US6130230 Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
10/10/2000US6130221 Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
10/10/2000US6130204 Peptides
10/10/2000US6129925 Container filled with infusion liquids and infusion preparation
10/10/2000US6129913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
10/10/2000CA2030516C Parathyroid hypertensive factor
10/05/2000WO2000058733A2 Assay for testing the efficacity of a therapy
10/05/2000WO2000058523A1 Glucocorticoid receptor agonist and decreased pp5
10/05/2000WO2000058496A1 50 human secreted proteins
10/05/2000WO2000058475A2 Streptococcus pneumoniae antigens
10/05/2000WO2000058472A2 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same
10/05/2000WO2000058467A1 50 human secreted proteins
10/05/2000WO2000058460A2 Casb619 involved in colon cancers
10/05/2000WO2000058348A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
10/05/2000WO2000057922A1 Intramyocardial injection of autologous bone marrow
10/05/2000WO2000057916A1 Sphingomyelin containing preparation for the enhancement of tumor therapy
10/05/2000WO2000057915A1 Method of affecting cholesterol catabolism using nuclear bile acid receptor
10/05/2000WO2000057914A1 Ocular tension-lowering agents
10/05/2000WO2000057907A2 Multivalent dengue virus vaccine
10/05/2000WO2000057900A2 Factor for regulation of neurite growth
10/05/2000WO2000057899A1 Thrombospondin-2 and uses thereof
10/05/2000WO2000057896A1 Modulators of polysaccharides and uses thereof
10/05/2000WO2000057892A1 Use of a serenoa repens extract for the production of a medicament to treat prostate cancer
10/05/2000WO2000057891A1 Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
10/05/2000WO2000057883A1 Use of vasopeptidase inhibitors to treat angina pectoris
10/05/2000WO2000057882A1 Concomitant drugs for preventing or treating infection with gram-positive bacteria
10/05/2000WO2000057878A1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment
10/05/2000WO2000057875A1 Compositions containing tea catechins as cancer specific proliferation inhibitors
10/05/2000WO2000057869A2 Viral treatment
10/05/2000WO2000057866A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections
10/05/2000WO2000057862A2 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases
10/05/2000WO2000057861A2 Use of cytidine derivatives for the treatment of leukaemia
10/05/2000WO2000057858A1 Sublingual buccal effervescent
10/05/2000WO2000057853A2 Pharmaceutical composition containing an extrusion additive
10/05/2000WO2000057852A2 Methods and compositions for treating solid tumors
10/05/2000WO2000057837A2 Compositions and methods for effecting the levels of cholesterol
10/05/2000WO2000057729A2 Beverages for treatment of glucose metabolism disorders
10/05/2000WO2000057721A2 Edible solids for treatment of glucose metabolism disorders
10/05/2000WO2000042026B1 Non-peptide glp-1 agonists
10/05/2000WO2000032178A3 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
10/05/2000WO2000031133A3 Potassium channel interactors and uses therefor
10/05/2000WO2000030588A3 Treatment of hypertension
10/05/2000WO2000026246A3 Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof
10/05/2000WO2000026243A3 Transmembrane 4 proteins
10/05/2000WO2000020625A9 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
10/05/2000WO2000011167A3 Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof
10/05/2000WO2000001716A3 Vasculoprotector
10/05/2000WO1998041232A3 Compositions for modulating responsiveness to corticosteroids
10/05/2000DE19916383A1 Pharmazeutische Zusammensetzung mit einem Extrusionsstoff A pharmaceutical composition comprising an extrusion material
10/05/2000CA2707691A1 Sphingomyelin containing preparation
10/05/2000CA2370441A1 50 human secreted proteins
10/05/2000CA2369009A1 Factor for regulation of neurite growth
10/05/2000CA2368881A1 50 human secreted proteins
10/05/2000CA2368674A1 Multivalent dengue virus vaccine
10/05/2000CA2368657A1 Thrombospondin-2 and uses thereof
10/05/2000CA2368616A1 Use of vasopeptidase inhibitors to treat angina pectoris
10/05/2000CA2368234A1 Method of affecting cholesterol catabolism using nuclear bile acid receptor
10/05/2000CA2368014A1 Casb619 involved in colon cancers
10/05/2000CA2367882A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
1 ... 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 ... 1151